Oncology Books
Nova Science Publishers Inc Horizons in Cancer Research: Volume 58
Book SynopsisThis book presents original results on the leading edge of cancer research. Topics discussed include oral cancer cachexia; the immunological mechanisms of cachexia; research in gynaecologic oncology today; advances in cellular understanding of muscle wasting in cachexia; and next generation sequencing developments in cancer research by bioinformatics approaches.
£195.19
Nova Science Publishers Inc Horizons in Cancer Research: Volume 59
Book SynopsisThis book presents original results on the leading edge of cancer research. Topics discussed include imaging of chondrosarcoma; novel nutrient mixtures inhibiting chondrosarcoma invasion and metastasis parameters; defective estrogen signaling is the highest risk for breast cancer; review of the cancer genomic landscape; reprogramming of metabolic pathways and cancer stem like cells; promising natural products as anti-cancer agents against neuroblastoma; oncofertility; and molecular mechanisms involved in myelodysplastic syndromes.
£195.19
Nova Science Publishers Inc Fighting Lung Cancer with Conventional Therapies
Book SynopsisLung cancer, the most common and deadliest malignancy worldwide, is one of the biggest challenges for modern oncology. Although lung cancer presents the same incidence as breast or colorectal cancer, it causes as much deaths as breast and colorectal cancers together. Lung cancer demands our abilities as researchers, physicians, and care-givers in a multidisciplinary approach. Genetic, biology, pharmacy, pneumology, internal medicine, radiology, pathology, thoracic surgery, radiation, medical oncology and palliative care departments are essential members of the thoracic tumor boards. Fighting Lung Cancer through Conventional Therapies is the second volume of a saga entirely devoted to the treatment of lung cancer. In the age of targeted oncology, more than 90% of lung cancer patients are managed with conventional surgery, radiation, and chemotherapy only. Furthermore, 100% of them will need conventional treatments during the course of the disease. This volume updates indications, techniques, and applications of surgery, radiotherapy and chemotherapy in the treatment of lung cancer by an international team of experts. Included within these pages are: epidemiology and pathology; baseline and mediastinal staging; minimally invasive surgery, video-assisted thoracic surgery, and standard surgery in early-stage non-small cell lung cancer; radiation therapy for early non-small cell lung cancer; the management of locally advanced non-small cell cancer; applications of surgery to metastatic lung cancer; the new role of radiotherapy in metastatic non-small cell lung cancer; conventional chemotherapy as well as experimental treatments and combos with targeted therapies; the treatment of early and advanced small cell lung cancer; the role of palliative supportive care; and the integration of all those disciplines in multidisciplinary tumor boards are exhaustively reviewed.
£230.39
Nova Science Publishers Inc Psychoneurocybernetic Conquest of Carcinogenesis
Book SynopsisThe book Psychoneurocybernetic Conquest of Carcinogenesis and Cancers is written to be understood by the informed layman as well as by scientists. It should be of special interest to physicians, health-care givers and laymen who want to know about the latest knowledge concerning the true cause of all cancers and their prevention, diagnosis and modern therapy. It will surely inform and entertain anyone who cares about ethics in medicine or the funding of medical research, including references to original scientific and popular literature. According to general (not only medical) knowledge, based upon personal experiences in conservative, surgical, thermo- and radiotherapy of neoplasms over many years, the authors have presented the dissipative nature of cancer so that everyone could understand the neoplastic diseases, the modern rules of psycho-oncology and the primary significance of one''s own lifestyle in the formation and progress of cancer along with importance of caring about the environment inhabited by people. They have summarized the public reactions to cancer and infertility in relation to the historic discovery of natural psychoneurocybernetic cause of cancer, mathematical interpretation of its cause, obstetrical prevention of human cancers and psycho-neuro-endocrine therapy of diseases, especially caused by baneful information.
£999.99
Nova Science Publishers Inc Encyclopedia of Lung Cancer
Book SynopsisThis encyclopedia presents important research on lung cancer. Some of the topics discussed herein include therapeutic antibodies in non-small cell lung cancer; radiation therapy; epigenetics; paraneoplastic syndromes associated with lung cancer; palliative radiotherapy treatments; bone and lung metastases; and asymptomatic presentation of lung and bone metastases in patients with breast cancer.
£209.59
Nova Science Publishers Inc Gastrointestinal Stromal Tumors in Adults &
Book SynopsisThis book provides a comprehensive overview of the epidemiology, clinical features, radiology, classification, molecular genetics, diagnosis and treatment of gastrointestinal stromal tumors in both adults and children. Various chapters of the book summarise all the important research findings and provide an updated text for all those involved in the research and clinical management of this tumor. This book is written by experts in the field from all over the world who have considerable research, clinical interest and experience in the management of this tumor. The book is a concise review of the relevant basic and clinical research on gastrointestinal stromal tumors, and provides a summary of their current classification, diagnosis and treatment strategies in both adults and children. It intends to provide a deep insight into the current knowledge on the subject and summarises all the important relevant data. It contains numerous radiologic and pathologic images, research illustrations and data that is valuable in the overall understanding of all aspects of this important tumor. This book is intended for researchers, students, paramedical staff, patients and doctors involved in the management of patients with this tumor, including gastrointestinal physicians, pediatricians, oncologists, surgeons, radiologists and pathologists. By reading this book, patients gain insight into the management of their own tumors, students find a platform on which they can build their research projects, and nurses and doctors maintain an overall understanding of the subject.
£999.99
Nova Science Publishers Inc Cancer: Pain & Symptom Management
Book SynopsisMany cancer patients experience a variety of distressing symptoms, adversely affecting their functional status and quality of life (QOL). Subjective symptoms such as pain, fatigue and depression are common among cancer patients, with approximately 33-55% of cancer patients experiencing pain during the course of their illness. Previous literature commonly examined a single symptom and its effect on patients'' functional status and QOL, but patients often experience multiple symptoms simultaneously. Since individual symptoms are often associated with decreased QOL, the assumption that symptom clusters might have a greater effect on QOL is logical. The coexistence of symptoms provides an insight into the importance of assessing clusters of symptoms rather than focusing on individual symptoms. Although the focus of single symptoms has advanced the understanding of those particular symptoms, it may not be as helpful to health care professionals in guiding practice when patients present several concurrent symptoms. It is important for clinicians to address and ultimately treat all concurrent symptoms. Symptom cluster research will help our understanding and treatment of multiple symptoms.
£113.59
Nova Science Publishers Inc Cancer: Treatment, Decision Making & Quality of
Book SynopsisIn early stages of cancer, patients are often presented with treatment options and encouraged to have shared treatment decisions with their oncologists. Shared decision making becomes particularly important, as several treatment options with different possible outcomes and adverse events exist. For example, women with early breast cancer are counseled on the options of mastectomy versus lumpectomy and radiation. The same principle should also apply in late stages of cancer, where cure is usually not possible in patients with widespread metastases. In these cases, the aim of treatment should be to relieve symptoms and suffering. Improving quality of life (QOL) rather than tumor control takes priority in palliative care. QOL has also been identified as an important endpoint for new cancer drugs, as determined by the Food and Drug Administration (FDA); as such, cancer drug approval can be based on improvement of QOL. The use of patient-reported QOL instrument tools help clinicians determine if certain treatments improve QOL. The research of palliative interventions should have QOL assessment to assist clinicians, patients and their family members in shared decision making.
£148.79
Nova Science Publishers Inc Acute Myeloid Leukemia: Signs/Symptoms,
Book SynopsisAcute myeloid leukemia (AML) is an aggressive bone marrow cancer associated with high morbidity and mortality and most commonly affects older patient populations. In this book, the clinical presentation of acute myeloid leukemia are presented. Other chapters present the differences in the outcomes of two subtypes of core binding factor (CBF) acute myeloid leukemia (AML); examine the occurrence of the Philadelphia chromosome in AML with core binding factor leukemia; and therapeutic options of older patients with AML.
£999.99
Nova Science Publishers Inc Handbook on Ovarian Cancer: Risk Factors,
Book SynopsisOvarian cancer is the third most diagnosed gynecologic cancer and the first leading cause of death from all of gynecological malignancies. High mortality of the patients is usually associated with the progression of the disease. Most patients are diagnosed within the advanced stages due to lacking relevant diagnostic and screening markers. This handbook discusses several risk factors of ovarian cancer. It also examines the different therapies provided to ovarian cancer patients, and the prognosis of the cancer.
£209.59
Nova Science Publishers Inc Cancer: Spinal Cord, Lung, Breast, Cervical,
Book SynopsisIn Canada over the past fifteen years, there has been a 39% rise in new cancer patients, necessitating the expansion of current oncological facilities. The population is getting older and larger, which in turn is translating into more cases of cancer. Other reports projecting cancer growth across different countries found similar results. With the prevalence of cancer expected to increase in the future, it is important to properly allocate resources towards cancer research to better serve the population. Patients with cancer continue to live longer; as such, more elderly individuals will live with cancer. In fact, cancer has been classified as a chronic illness alongside diabetes, hypertension, and heart disease. This may translate to an increased demand for oncologists, specialist-trained nurses, diagnostic services, cancer centres, cancer therapies and palliative care. More importantly, this will translate to an increased necessity for cancer research to decrease the mortality and morbidity associated with cancer while improving the quality of care.
£195.19
Nova Science Publishers Inc Cancer: Survival, Quality of Life & Ethical
Book SynopsisSeveral medical options in palliative care can have complex moral, religious, cultural, medical and legal issues. These treatment options, such as assisted suicide, rehydration, parenteral nutrition and cardiopulmonary resuscitation have been heavily debated in the literature. Physician-assisted suicide is a controversial topic for debate, with growing pressure from advocacy groups for legalisation in regions that have yet to decide. Currently, there is substantial opposition from concerned medical professionals. However, a school of medical professionals acknowledges that physician-assisted suicide may have a role in terminal care. The debate over the use of artificial nutrition and hydration (ANH) in terminal illness is also contentious despite extensive ethical and empirical research. Advocates for and against ANH both agree that the most compassionate and humane option for patients near the end of life is hospice and/or palliative care. However, many of those who support ANH do not seem to appreciate that the standard palliative practice is to avoid the use of ANH in almost all instances. These topics remain heavily disputed in the medical community. In formulating a satisfactory answer, we need to remind ourselves that we cannot generalise a treatment as a correct or incorrect option. Rather, we need to consider each case individually, weigh the risks and benefits of each treatment, and individually consider treatment options in a multidisciplinary care model.
£148.79
Nova Science Publishers Inc Cancer: Bone Metastases, CNS Metastases &
Book SynopsisWith effective systemic therapy and comprehensive supportive care, patients with metastases can live longer. Breast cancer patients with only or predominantly bone metastases have a median survival of 2.3 years following diagnosis, while metastatic prostate cancer patients have a median survival time of 11.3 months. With recent advances in research, the overall survivorship of metastatic patients has increased. The improved quality of care for metastatic cancer patients has resulted in longer survivorship. Living longer can lead to a higher chance of development for skeletal-related events (SREs), which are defined as either spinal cord compression, hypercalcemia, pathological fractures or a need for palliative radiation therapy or surgery for bone pain. To try to reduce pathological fractures, it is important to detect impending fractures earlier and to administer prophylactic surgery as needed. Longer survivorship also allows time for the development of brain metastases. Recent advances incorporating stereotactic radiosurgery (SRS) have been favored over conventional whole-brain radiation therapy (WBRT) in the preservation of neurocognitive functions and survival benefit in patients less than 50 years of age. Multidisciplinary clinics for brain metastases are again desirable with the joint input of the radiation oncologists and neurosurgeons.
£163.19
Nova Science Publishers Inc Horizons in Cancer Research: Volume 60
Book SynopsisThis book presents original results on the leading edge of cancer research. Lipomas are extremely common benign lesions, representing the most common softtissue tumor, with a wide spectrum of clinical presentations and imaging appearances. Several subtypes are described, ranging from lesions entirely composed of mature adipose tissue to tumors intimately associated with nonadipose tissue, to those composed of brown fat. Chapter one begins with an overview of the available evidence about the classification, clinical manifestations, diagnostic tests and treatment options of lipomas. The following three chapters examine parosteal lipomas and giant lipomas. Chapter five studies the first literary description of cavernous angiolipoma of the subcutis in a 75-year-old man, delivering a new lipomatous entity. Chapter six focuses on immune plasticity and susceptibility to cancer from fanconi anemia, which is characterised as a genetic disorder of genomic instability, with main clinical symptoms involving congenital abnormalities, infertility, bone marrow failure and a predisposition to the development of several types of cancer, especially acute myelogenous leukemia (AML) and head and neck carcinomas. Chapter seven discusses radiotherapy for patients with fanconi anemia. Chapters eight and nine examine the effects of ursolic acid (UA) and flavonol-enriched extract (FL) on the cell cycle behaviour of DU145 human prostate cancer cells in vitro. Chapter ten describes the most current advances made in characterising the role of PLA2 in tumor development and progression, as well as highlight some of our most recent studies involving iPLA2 and cancer. The remaining chapters discuss the preclinical rationale for targeting human EGFR and recent clinical reports of targeted agents in esophageal cancer; study the pharmaceutical properties and drug likeness of anticancer drugs administered for the clinical treatment of lung cancer; and covers the epidemiology, different etiology and pathogenesis of hepatocellular carcinoma.
£163.19
Nova Science Publishers Inc Hepatocellular Carcinoma in the 3rd Millennium
Book SynopsisHCC is the most common primary cancer of the liver and according to the WHO report, the fourth commonest cause of death. The estimated incidence of new cases worldwide is about 500,000-1,000,000 per year causing 600,000 deaths globally per year. Although there are large areas of the world where the incidence of HCC is still unknown, several countries in East Asia and some Sub-Saharan African regions are affected by a very high prevalence of HCC (over 20 cases/100,000 population). Areas with a moderately high risk (11-20 cases/100,000 population) include Italy, Spain and Latin America, while France, Germany and the United Kingdom have instead an intermediate risk (5-10 cases/100,000 population). A relatively low prevalence (less than 5 cases/100,000 population) is found in the United States, Canada and Scandinavia. The incidence of HCC has been rising in developed western countries in the last two decades, along with the emergence of the hepatitis C virus infection and due to the rise of immigration rates from HBV-endemic countries. In addition, even though the incidence of HCC reaches its highest peak among persons over 65 years, an increased incidence among younger individuals has been noted in the last two decades both in USA and Europe. A multidisciplinary approach should be taken when assessing patients with HCC; stage of HCC and liver disease should always be taken into account and the best treatment should be offered. Liver resection and ablative treatments should never be denied to patients, and curative procedures should be performed in hepato-biliary-pancreatic centers. Each HCC patient has to be evaluated singularly, stratifying each time the risk for the procedure so as to determine which treatment is the best treatment. It is also important to analyse all the possibilities that can be offered. This similar approach showed a good efficacy and safety in all "frail" patient categories, such as elderly patients or patients with HCC and HIV infection. Early diagnosis of HCC and retreatment for HCC recurrence have a key role in the survival of patients. Therefore, regular screening programs for HCC should be extended to all patients according to proposed guidelines, together with a greater proclivity for treatment and retreatment options in cases of an HCC diagnosis or recurrence. This may be an important and needed breakthrough for this rising problem.
£163.19
Nova Science Publishers Inc Oligodendrogliomas (ODs): Diagnosis, Outcomes &
Book SynopsisCancer is the second leading cause of morbidity and mortality worldwide, ranking just after cardiovascular diseases. In the central nervous system, gliomas constitute the most frequent type of tumors. According to the definition, oligodendrogliomas are diffusely infiltrating glial tumors, composed of neoplastic oligodendroglial cells, typically found in cerebral hemispheres in adult population, although not uncommon in children. They encompass a range of tumours, from well-differentiated to frankly malignant neoplasms. In the current World Health Organization (WHO) classification of tumors of the central nervous system, covering a four-tiered WHO grading scheme, oligodendrogliomas are recognised as grade WHO II and WHO III by the degree of malignancy. They may be either well differentiated, composed of neoplastic cells that morphologically resemble oligodendroglia, or may harbor focal or diffuse features of malignancy, respectively. Their prognosis is in this case less favorable. This book provides current research on the diagnosis, outcomes and prognosis of oligodendrogliomas. Chapter one examines the pathology, molecular mechanisms and clinical references of ODs. Chapter two discusses the ODs and the problematic diagnostic markers. Chapter three examines the histopathologic features of oligodendrogliomas and of an assortment of other central nervous system neoplasms that can resemble them and reviews features that allow one to sort through these histopathologic differential diagnoses. The final chapter reviews speech mapping in oligodendroglioma operations and provides data regarding patient outcomes with these methods.
£113.59
Nova Science Publishers Inc Diffuse Large B-Cell Lymphoma (DLBCL): Symptoms,
Book SynopsisThe diagnosis and treatment of Diffuse large B-cell lymphoma (DLBCL) have evolved significantly in the past decade. With advances in our understanding of DLBCL through the application of immunophenotypic, molecular cytogenetic analysis and clinical correlation, a growing number of discrete subtypes and entities of DLBCL have been recognised, along with improved prognostic stratification and treatment strategies. A simple diagnosis of DLBCL and standard chemotherapy are no longer appropriate for every individual patient anymore. Pathologists and practicing clinicians need to be familiar with current literature in order to achieve the best treatment of their patients. This book aims to provide the most up-to-date knowledge of the diagnosis, prognosis and treatment strategies of DLBCL. Each chapter focuses on a different subject of DLBCL: pathology, prognosis, chemotherapy regimens and future directions, role of radiation therapy and hematopoietic stem cell transplant, and treatment strategies, as well as special considerations in the treatment of the most common subtypes of DLBCL. The authors are practicing physicians in major medical centers and university hospitals, and are familiar with the challenges of diagnosing and treating patients with DLBCL. The book is written for practicing physicians and provides practical information and advice for their daily practice. Residents, fellows and physicians in their early career development will also find the contents of this book useful for their education and board preparation. The authors hope that the material covered in this book will serve as a foundation for readers to keep up with future developments in this specific field of study.
£163.19
Nova Science Publishers Inc Ependymomas: Prognostic Factors, Treatment
Book SynopsisThis book provides research on ependymomas, a rare brain tumor that arises from the ependymal cells of the intra-ventricular central nervous system (CNS) parenchyma with a propensity to affect both children and adults. Ependymomas account for only 1.9% of all primary brain and CNS tumors. Chapter One discusses the prognosis and outcomes in patients with ependymal tumors. Chapter Two investigates the effects of gender, age, race, tumor grade, and treatment on clinical outcomes of ependymoma diagnosed patients. Chapter Three examines survival rates, and prognostic factors. Chapter Four contains a contemporary review of the literature and an evidence-based systematic review about intraspinal ependymomas (ISE). Chapter Five reviews literature on ependymal neoplasms arising in the setting of hereditary tumor syndromes. Chapter Six discusses the current management of pediatric ependymomas and examines evolving biological data.
£999.99
Nova Science Publishers Inc Horisons in Cancer Research: Volume 61
Book SynopsisThis book presents original results on the leading edge of cancer research. Chapter One explains unanswered questions of contemporary oncology from the standpoint of karyogamic theory of carcinogenesis. Chapter Two focuses on the molecular players of the human papillomaviruses (HPVs) infection leading to chronic inflammation and cancer. Chapter Three describes Multiple Myeloma (MM), and Monoclonal Gammopathy of Undetermined Significance (MGUS). Chapter Four reviews the role of choline metabolites as second messengers in cellular pathways leading to enhanced cell survival, migration, and proliferation to explore the possibility that "in-vivo" imaging of choline metabolism can be used to obtain readouts of cell signal transduction in cancer. Chapter Five investigates the possible correlation between anatomic melanoma distribution on the specific back area and lack of sunscreen application. Chapter Six describes the known molecular mechanisms of epigallocatechin (EGC) and epigallocatechin-3-gallate (EGCG) in malignant neuroblastoma that can help find new directions for future research. Chapter Seven discusses the burdens of childhood cancer survivorship and the consequences of different treatment therapies on the incidence of CVD and explores potential monitoring methods and the need for consistent cardiovascular monitoring of childhood cancer survivors regarding their cardiovascular health. Finally, Chapter Eight considers a model for implementing recommendations pertaining to Lynch syndrome, and also looks at what is happening in the field now to support Lynch syndrome genetic testing and surveillance, and how a deliberative conference can point the way to changes that need to take place to deliver screening to those at risk.
£163.19
Nova Science Publishers Inc Targeted Therapies in Cancer: An Update
Book SynopsisBesides surgery, radiation therapy, endocrine therapy or chemotherapy, which were widely used in cancer patients for decades, the 21st century has seen the emergence of "targeted" therapy, resulting from the identification of molecular pathways in cells and their alterations in tumors. An increasing number of compounds targeting specific molecules or cancer cells have been developed and, for some of them, approved by the United States Food and Drug Administration (FDA) as well as other regulators in EU and Japan Additional new and more efficient types of compounds, are still in clinical trials, but are expected to gain future approval. More than eighty FDA-approved targeted therapies are described here, along with about eighty other promising compounds. These drugs are members of various therapy classes, including tyrosine kinase inhibitors; serine/threonine kinase inhibitors; dual specificity kinase inhibitors; lipid kinase inhibitors; poly ADP ribose polymerase inhibitors; monoclonal antibodies; microtubule targeting agents; histone deacetylase inhibitors; proteasome inhibitors; antimetabolites; immunomodulatory agents; DNA methyltransferase inhibitors; hedgehog pathway inhibitors; enzymes; protein translation inhibitors; vaccines, oncolytic viruses; chimeric antigen receptor T-cells (CAR-T); and so on. A series of "companion" diagnostics intended to be used as an indication for specific therapies, and approved to this aim are also mentioned. The book aims to present the broad landscape of compounds and companion diagnostics that are expected to pave the way towards a future of hope for cancer patients.
£163.19
Nova Science Publishers Inc Bile Duct Cancer: Symptoms, Treatment & Prognosis
Book SynopsisPrimary bile duct cancers are rare and generally aggressive entities. Historically, this disease was managed exclusively with surgical therapy with few long-term survivors. However, with improvements in chemotherapeutics, targeted therapy, interventional radiology techniques and development of alternative surgical approaches, treatment has moved to the utilization of a multidisciplinary care team employing multimodality treatments which has finally led to improvement in outcomes. In this book, Chapter One examines symptoms and the current state of medical and surgical management of bile duct cancer, while Chapter Two discusses the clinical aspects of care of extrahepatic biliary cancers with an emphasis on diagnosis and management. Chapter Three assesses the risk of bile duct cancer among beneficiaries of The Health Insurance Society of Printing Industry (HISPI) using diagnosis-procedure-combination (DPC) data in comparison with general population. Chapter Four concludes with a summary of results for chemotherapy and targeted therapies.
£83.29
Nova Science Publishers Inc Diversity, Versatility & Leukaemia
Book SynopsisThe blood cell system has provided a model system that has been used by many researchers to investigate how a stem cell can give rise to a wide variety of mature cell types. The principles that emerged in developmental biology have been applied to the structure of tissues throughout the body. However, many of the principles have been challenged by recent findings, changing the way we view blood cell development. In turn, this has impacted our understanding of the origin and nature of leukaemia, as well as cancer in general. Like the development of any body tissue, cancer is an organised and hierarchical tissue with its own identity. A new viewpoint is that the mutations that give rise to cancer re-programme cancer cells to their own abnormal pattern of tissue development. Understanding how the hierarchy of tumour identity differs from that of normal tissue provides important new avenues to the development of new treatments for cancer. No doubt further refinement to our understanding of normal and cancer cells will continue for many years to come. Even so, we appear to be moving towards an exciting prospect of providing the key to unlocking the long standing mystery of primary cellular events that undermine and distort our normal cells and give rise to the disease of cancer. The importance of this is the prospect of developing new treatments for cancer. In particular, the distorted behaviour of cancer cells might be reversible so that they can be restored to their normal state. Diversity, Versatility and Leukaemia examines how normal and cancer cells are inextricably linked, and focuses on the changes to how we view the development of normal cells and the subversion of this process in cancer.
£999.99
Nova Science Publishers Inc Easy Book of Cancer Pharmacology
Book SynopsisThis book represents the efforts of young oncologists, haematologists, pharmacists and oncology nurses who are highly motivated and encouraged by the significant development of new effective anticancer drugs. Since the discovery of antimetabolites and alkylating agents in the 1940s and 1950s, many new products have been introduced into our daily arsenal not only through chemotherapy agents, but also by means of biological or immunotherapeutic drugs whose side effects differ significantly. The idea of this book was born from a simple observation and confirmation of fact. New doctors in training experience high levels of stress and lack of confidence when confronting cancer patients and explaining a treatment or managing frequent side effects. Patients questions will only add more nervousness, and this will lead to a failure in the doctor-patient relationship, causing the patients mistrust and doctors frustration. Nurses dealing with these patients will suffer pressure too, as many questions regarding antineoplastic drugs will be asked of them and patients expect them to ease their doubts. This feeling of vulnerability in front of a patient, though a part of the maturation process when becoming a professional caretaker, causes discomfort and incertitude. In this context, it is crucial to gain great knowledge about pharmacokinetic and pharmacological features of each active anticancer drug used, as well as the indications, dosages, interactions and toxicities, to be able to face the daily practice of oncology without concerns and manage daily therapeutic complications easily. This may be considered very difficult, taking into account the huge number of active agents doctors manage routinely, but doctors have accepted the challenge and designed a straightforward, comprehensible book to solve this issue. The Easy Book of Cancer Pharmacology provides the means to overcome the problem. It is conceived as an accessible, concise and yet exhaustive tool which displays a vast amounts of knowledge in a very schematic way. It is easy to consult and offers a very practical expertise to develop the ability of managing effectively each antineoplastic agent quickly. It gives the necessary insights to explain this to the patients with confidence. Each chapter reviews one active drug and shows the information with a pragmatic style, and they are divided into different sections. Each section covers distinct aspects of the agent, from general characteristics to more specific details related to clinical pharmacology. In quickly advancing fields such as oncology, such a book is necessary to help update the ever-developing and expanding knowledge of clinicians and patients in an efficient and effective manner.
£170.39
Nova Science Publishers Inc Pathological Diagnosis of Breast Cancer
Book SynopsisBreast tumours are one of the most worrisome and challenging problems for surgeons and pathologists. In this book, the authors present research in the study of the epidemiology, management and prevention of breast tumors; some examples of these types of breast cancer are DCIS, LCIS, IDC, ILC, medullary carcinoma, metaplastic carcinoma, papillary carcinoma, adenoid cystic carcinoma, and rare tumors of the breast. This book is useful to surgeons and pathologists, postgraduates in understanding the pathology for the diagnosis, treatment and prevention of these tumors.
£92.79
Nova Science Publishers Inc Breast Cancer: Risk Assessment, Treatment & New
Book SynopsisCancer risk prediction models provide an important approach to assess risk and susceptibility by identifying individuals at high risk, facilitating the design and planning of clinical chemoprevention trials, and allowing the evaluation of interventions. Conventional breast cancer risk model includes the cumulative estrogen exposure data such as age, age at menarche and menopause, age at first live birth, and use of HRT in risk calculation, since estrogens are the main risk factor for mammary carcinogenesis. The most widely known and commonly used model for breast cancer risk assessment is the Gail model, which focuses primarily on non-genetic risk factors, with limited information on family history. The first chapter of this book examines breast cancer risk assessment models. The following chapters discuss the association between obesity and breast cancer development; current and future standards for treatment of breast cancer and long term care of patients; and mastectomies and voluntarism.
£83.29
Nova Science Publishers Inc Horizons in Cancer Research: Volume 62
Book SynopsisThis book presents original results on the leading edge of cancer research. Chapter One summarizes what is currently known regarding the epigenetic regulation of osteosarcoma pathways and oncogenes, as well as clinical trials of drugs that exert epigenetic regulation. Chapter Two critically discusses the role of ECM-dependent signaling in osteosarcoma progression. Chapter Three illustrates the harmful effects of ultraviolet radiation exposure by focusing on photocarcinogenesis. Chapter Four examines the psychology of sunscreen use and outlines the key psychological factors associated with sunscreen use. Chapter Five reviews the cellular and molecular mechanism of Regulatory T cells (Tregs) and Transforming Growth Factor-β mediating cervical cancer development. Chapter Six examines the affect of the American cranberry extract on expression of insulin-like growth factor-I and insulin-like growth factor binding proteins in human prostate cancer cells in vitro. Chapter Seven discusses the design of synthetic peptides to specifically interfere the papillomavirus binding factor/14-3-3beta binding to restore papillomavirus binding factor apoptotic functions. Chapter Eight examines brain development using correlations between Diffusion Kurtosis and neurite orientation dispersion and density imaging (NODDI) in neonates and young children. Chapter Nine highlights the opportunities that are available to prevent the late effects related to stress and fears, emphasizing the importance of teaching patients resiliency and how to cope.
£205.59
Nova Science Publishers Inc Chronic Lymphocytic Leukemia: Diagnosis,
Book SynopsisChronic Lymphocytic Leukemia (CLL) is the most common leukemia in the western world, seen mostly in the elderly age-group and has a very variable clinical outcome. Traditionally considered an indolent, antigen inexperienced leukemia of slowly accumulating cells that do not die, researchers now acknowledge that CLL cells are highly proliferative, antigen experienced cells that have a high cell turnover and a subset show an aggressive clinical course. The onset of the disease is usually asymptomatic; only abnormalities in whole blood count such as leukocytosis with lymphocytosis are found. Nowadays, CLL is diagnosed more often at an early, asymptomatic stage due to more frequent routine blood tests. More advanced stages are characterized by lymphadenopathy, hepatomegaly/splenomegaly, recurrent infections, weakness, pallor and hemorrhagic diathesis, and general symptoms such as weight loss, fever and night sweats are observed. This book reviews the diagnosis, treatment options and prognosis of CLL.
£999.99
Nova Science Publishers Inc Understanding Cancer at the Subcellular Level
Book SynopsisThe human life is considered most vital of all the living creatures on Earth because humans are bestowed with the highest level of cognition. One can enjoy life if the natural gift, the body, is in a good or healthy condition. A disease is an abnormal condition of the body resulting from infections, toxicity, unfavourable environmental conditions, or illness due to inherited genetic defects in the body. In the past,contagious diseases like the plague resulted in widespread death. About 100 years ago tuberculosis (TB), which is caused by a single bacteria, was one of the deadliest diseases. However, today even a fourth stage TB patient can live a normal life after receiving the allopathic treatment. Unfortunately, that is not the case with cancer. Today cancer is the most dreaded disease and the #1 killer worldwide. Unlike TB, cancer is difficult to treat as there are more than 100 different types of cancers. However, with a communal undying zeal and drive for finding a cure for cancer, a lot of progress has been made recently in treating different types of cancers, some of them resulting in total cure. Understanding Cancer at a Subcellular Level delves into the root cause of cancer, which is the mutations in DNA molecules or genes. Further, it elaborates on the risk factors which cause mutations in genes. The internal causes are either inherited faulty genes from one of the parents or changes in genes due to the cells internal microenvironments; the external risk factors are many, such as age, alcohol, food, tobacco, etc. If your health is in good condition, that means your genes are quite healthy. If DNA or genes are mutated, it leads to cancer development. Multiple mutations in a single gene and multiple mutated genes are needed to develop cancer. Today, with advancements in science and technology, it is possible to offer various treatment options to cancer patients. The book gives details about: i) signs and symptoms of cancer; ii) causes or risk factors of developing mutations in a healthy gene using the concept of molecular biology at the genetic level; iii) different types of genes and cancers; iv) country specific treatment options; v) dealing with cancer; and vi) estimated treatment costs. The last chapter is dedicated to definitions of different terms used in this book. This book covers extremely vital information useful for scientists in research laboratories (such as chemistry, biochemistry, molecular biology, oncology, human genome, bioengineering/genetic-engineering etc.), general physicians, oncologists, all other medical practitioners, students and professors, cancer patients and their relatives and for anyone interested in learning about this abnormality.
£195.19
Nova Science Publishers Inc Advances in Carcinogenesis Research
Book SynopsisThis book introduces recent topics regarding carcinogenesis, including manifold findings of cell proliferation biology, abnormal cell division, pathophysiology, diagnosis, prevention and treatment implicated in the fields of cancer. Carcinogenesis is a multistep process initiated by external stimuli that lead to genetic changes in normal cells or stem cells, resulting in proliferation, apoptosis, dysplasia and neoplasia. The expression, post-translational processing, and targeting of the gene products are frequently altered in transformed and malignant cells. Currently, prognosis of advanced cancer remains poor in spite of the development of novel therapeutic strategies. Improved knowledge of the oncogenic processes and signaling pathways that regulate tumor cell proliferation, differentiation, angiogenesis, invasion and metastatis has led to the identification of several potential therapeutic targets, which have driven the development of molecularly targeted therapies. The target is drugable, as an enzyme (kinase) or cell surface molecule (membrane-bound receptors) that can be easily screened for small-molecule inhibitors or targeted by a specific antibody. New perspectives in cancer treatment have appeared with the advent of microRNAs, a novel class of noncoding small RNAs. Moreover, identification of the genes that are differentially expressed between sensitive and resistant cancer cells for chemotherapy and radiation is important in the ability to predict the clinical effectiveness of therapy and develop new therapeutic tools. This book provides recently discovered information concerning cancer biology as well as translational treatment for cancer patients.
£83.29
Island Press A New War on Cancer: The Unlikely Heroes
Book SynopsisFor more than fifty years, we have been waging, but not winning, the war on cancer. We’re better than ever at treating the disease, yet cancer still claims the lives of one in five men and one in six women in the US. The astonishing news is that up to two-thirds of all cancer cases are linked to preventable environmental causes. If we can stop cancer before it begins, why don’t we? That was the question that motivated Kristina Marusic’s revelatory inquiry into cancer prevention. In searching for answers, she met remarkable doctors, scientists, and advocates who are upending our understanding of cancer and how to fight it. They recognise that we will never reduce cancer rates without ridding our lives of the chemicals that increasingly trigger this deadly disease. Most never imagined this role for themselves. One scientist grew up without seeing examples of Indian-American women in the field, yet went on to make shocking discoveries about racial disparities in cancer risk. Another leader knew her calling was children’s health, but realised only later in her career that children can be harmed by invisible pollutants at their nursery. Others uncovered surprising links between cancer and the everyday items that fill our homes and offices. For these individuals, the fight has become personal. And it certainly is personal for Berry, a young woman whose battle with breast cancer is woven throughout these pages. Might Berry have dodged cancer had she not grown up in Oil City, Pennsylvania, in the shadow of refineries? There is no way to know for sure. But she is certain that, even with the best treatment available, her life was changed irrevocably by her diagnosis. Marusic shows that, collectively, we have the power to prevent many cases like Berry’s. The war on cancer is winnable - if we revolutionise the way we fight.Table of ContentsForeword by Philip Landrigan Introduction Chapter 1. Laurel: Safer Nourishment through Science Chapter 2. Ami: Safer Beauty through Racial Justice Chapter 3. Nse: Safer Little Ones through Politics Chapter 4. Bill: Safer Homes and Offices through Market Pressure Chapter 5. B. Braun: Safer Medical Treatment through Innovation Chapter 6. Melanie: Safer Neighborhoods through Activism Epilogue: Moving Beyond Survival
£20.89
Nova Science Publishers Inc Mesothelioma: Risk Factors, Treatment and
Book SynopsisMesothelioma is a type of cancer in which tumors form in the tissue that lines the lungs, heart, stomach, and other organs. While mesothelioma is relatively rare, it represents a serious health crisis as the disease is aggressive and often fatal. This book includes five chapters that detail the treatment and prognosis of the disease as well as the factors that put a person at risk for developing mesothelioma. Chapter One describes the most promising emerging immunotherapy combinations for the treatment of malignant pleural mesothelioma, discussing the biological rational underlying their development as well as the issues surrounding their clinical development. Chapter Two provides an overview of malignant mesothelioma, describing the history of its diagnosis and treatment as well as the role that asbestos exposure and other factors play in its development. Chapter Three revises the role of the main inflammatory and immunological markers as prognostic indicators in malignant pleural mesothelioma and discusses the surgical effects on immune response against cancer. Chapter Four explores the main cancer markers utilized for mesothelioma diagnosis as well as the new developments in the field. Lastly, Chapter Five examines the various surgical options available for removing pleural tumors.Table of ContentsPreface; Mesothelioma: The Advent of Immunotherapy; Malignant Mesothelioma; Inflammatory and Immunological Aspects in the Surgical Management of Malignant Pleural Mesothelioma; New Developments in Mesothelioma Markers; Surgical Approaches to Pleural Tumours; Index.
£72.24
Nova Science Publishers Inc Burkitt Lymphoma: Diagnosis, Risk Factors and
Book SynopsisBurkitt lymphoma (BL) is a form of non-Hodgkin's lymphoma in which cancer starts in immune cells called B-cells. If left untreated, it is rapidly fatal. Chapter One of this monograph evaluates the aetiology, pathological issues, diagnosis, clinical manifestations, epidemiology, research, innovation and treatment issues of BL using the clinical systematic review research method and experts' opinion analysis approach. Chapter Two reviews the spectrum, unique characteristics and special management considerations when BL develops in specific subgroups of patients with primary immune deficiency disorders. Chapter Three reviews the incidence, clinicopathological and epidemiologic features, treatment and outcome data available in paediatric and adult patients with post solid organ transplant BL. Chapter Four focuses on the pathobiology and the treatment of first-line and relapsed/refractory cases of BL and describes new therapeutic strategies which could improve results in this pathology. Chapter Five examines the therapeutic advances in BL and its variants. Finally, Chapter Six explores and emphasizes the trends and issues in research and innovation in the characteristics, clinical updates and management approaches of BL.Table of ContentsPreface; Burkitt Lymphoma: Diagnosis and Treatment Issues; Burkitt Lymphoma in Patients with Primary Immunodeficiency Disorders; Post Solid Organ Transplant Burkitt Lymphoma; Burkitt Lymphoma; Examining the Therapeutic Advances for Burkitt Lymphoma; Burkitt Lymphoma: Evaluation of Characteristics, Clinical Updates and Management Approaches Trends; Index.
£999.99
Nova Science Publishers Inc Horizons in Cancer Research: Volume 82
Book Synopsis
£177.59
Nova Science Publishers Inc Dendritic Cell Biology as an Immune Dysfunction
Book SynopsisThis monograph deals with the susceptibility issues in the development of an effective response to antigenicity as presented by emerging or established neoplastic lesions. An attempt has been made to present critical views of the dysfunction of carcinogenesis in terms of evolving immune responses in terms of recruitment of dendritic cell biology. It is within such conceptual framework that autoimmunity presents an attractive response to neoplasia in terms that allow for access to the malignant transformation process. It is significant to potentiate the immune responses that involve the integral immune dimensions that characterise and recharacterise the dynamics of turnover of dendritic cells as the most powerful agents in presentation of neoantigenicity as provided by tumour cell proliferation and spread within the body. The performance of staged dimensions in antigen exposure by tumour cells is critical to the presentation of tumour cells as brought forward by the proposed dynamics of an interface between tumour cells and the tumour microenvironment in the realisation of an extensive autoimmune response with the realisation of performance exposure of the antigenicity as a biologic agent in its own right. This book is aimed to cancer researchers, pathologists, and immunologists with a strong interest in carcinogenesis and cancer cell progression as dictated by proposed immune response to tumour antigenicity.
£72.24
Nova Science Publishers Inc Horizons in Cancer Research: Volume 83
Book SynopsisThis volume includes seven chapters that present some of the latest advancements in cancer research. Chapter One studies the correlation between smoking and cancer using the sequenced human genome. Chapter Two discusses glucose-regulated protein 78-mediated regulation of epithelial-mesenchymal transition, the apoptotic and autophagic signaling pathways, and how it can be used as a therapeutic against cancer. Chapter Three discusses new approaches in the treatment of hodgkin lymphoma. Chapter Four includes a review of the etiology, diagnosis and therapeutic management of rare pancreatic tumors. Chapter Five introduces recent progress on the mechanism of action and predictive biomarkers of mitomycin C using a genome-scale CRISPR/Cas9 knockout screening approach. Chapter Six discusses ultrasonography, endometrial sampling, magnetic resonance imaging, and computed tomography in the context of endometrial cancers. Finally, Chapter Seven discusses treatment options for papillary thyroid carcinoma.
£177.59
Nova Science Publishers Inc Platinum-Based Chemotherapy: Clinical Uses,
Book SynopsisAccording to the Global Cancer Observatory, in 2020 the number of new cases of cancer was 19.3 million people in the whole world, with breast, lung, and colorectal cancer comprising 10-11% each of these figures. In the same year, there were almost 10 million deaths from cancer, with lung cancer being the one leading to more deaths (18%). Unfortunately, these figures are only expected to increase, with an estimated incidence of 30.2 million cases in 2040. Thus, cancer is a worldwide public health priority, with a high socio-economic impact. Chemotherapy stands out among the available cancer treatments. Platinum-based chemotherapy is one of the earliest chemotherapeutics introduced to the clinics and it is still the first-line treatment, used alone or in combination with other anti-neoplastic therapy and/or radiation, for many types of cancer in both adults and children. The book Platinum-Based Chemotherapy: Clinical Uses, Efficacy and Side Effects offers the reader a general overview of this therapy, as well as an update on some of the most relevant issues specific to this therapy.
£163.19
Evidence-Based Networks Ltd Fundamentals of Cancer Care
Book SynopsisAs the range of successful treatments for cancer expands, demand for skilled and trained nursing teams is growing. This new text supported by the UK Oncology Nursing Society, and written by a team of over 30 experienced practitioners, provides an illustrated primer for anyone training to be a nurse or embarking on specialist training in the field.
£23.74
Royal Society of Chemistry Cytotoxic Payloads for Antibody–Drug Conjugates
Book SynopsisAntibody–drug conjugates (ADCs) represent one of the most promising and exciting areas of anticancer drug discovery. Five ADCs are now approved in the US and EU [i.e., ado-trastuzumab emtansine (Kadcyla™), brentuximab vedotin (Adcetris™), inotuzumab ozogamicin (Besponsa™), gemtuzumab ozogamicin (Mylotarg™) and moxetumomab pasudotox-tdfk (Lumoxiti®)] and over 70 others are in various stages of clinical development, with impressive interim results being reported for many. The technology is based on the concept of delivering a cytotoxic payload selectively to cancer cells by attaching it to an antibody targeted to antigens on the cell surfaces. This approach has several advantages including the ability to select patients as likely responders based on the presence of antigen on the surface of their cancer cells and a wider therapeutic index, given that ADC targeting enables a more efficient delivery of cytotoxic agents to cancer cells than can be achieved by conventional chemotherapy, thus minimising systemic toxicity. Although there are many examples of antibodies that have been developed for this purpose, along with numerous linker technologies used to attach the cytotoxic agent to the antibody, there is presently a relatively small number of payload molecules in clinical use. The purpose of this book is to describe the variety of payloads used to date, along with a discussion of their advantages and disadvantages and to provide information on novel payloads at the research stage that may be used clinically in the future.Trade ReviewPlan on having this sitting on your desk shelf as the definitive guide to ADC payloads for the next 5-10 years. -- Justin Sweeley, Novasep * 5 Things You Need To Know This Week About ADCs – July 27, 2019 ADCReview *Table of ContentsIntroduction to Antibody-Drug Conjugates (ADCs); Design Factors Important for Antibody-Drug Conjugate (ADC) Payloads; Use of Molecular Modelling Techniques in Antibody-Drug Conjugate (ADC) Payload Discovery and Development; Auristatin Payloads for Antibody-Drug Conjugates (ADCs); Maytansinoid Payloads for Antibody-Drug Conjugates (ADCs); Colchicine-, Vinblastine-, Taxol- and Eribulin-based Payloads for Antibody-Drug Conjugates (ADCs); Traditional Cytotoxic Agents as Antibody-Drug Conjugate (ADC) Payloads; Topoisomerase Inhibitors as Antibody-Drug Conjugate (ADC) Payloads; Duocarmycins as Antibody-Drug Conjugate (ADC) Payloads; CXI Dimers as Antibody-Drug Conjugate (ADC) Payloads; Duocarmycin-PBD Dimers as Antibody-Drug Conjugate (ADC) Payloads; Calicheamicins as Antibody-Drug Conjugate (ADC) Payloads; Pro-pyrrolobenzodiazepines and Conjugates as Antibody-Drug Conjugate (ADC) Payloads; Pyrrolobenzodiazepine Dimers as Antibody-Drug Conjugate (ADC) Payloads; Indolinobenzodiazepine Dimers (IGNs) as Antibody-Drug Conjugate (ADC) Payloads; Pyridinobenzodiazepines (PDDs) as Sequence-selective DNA Mono-alkylating Antibody-Drug Conjugate (ADC) Payloads; Splicing Inhibitors as Antibody-Drug Conjugate (ADC) Payloads; Tubulysins as Antibody-Drug Conjugate (ADC) Payloads; Amatoxins as RNA Polymerase II Inhibiting Antibody-Drug Conjugate (ADC) Payloads; Protein Toxins as Antibody-Drug Conjugate (ADC) Payloads; Occupational Health and Safety Considerations for the Handling and Manufacture of Antibody-Drug Conjugate (ADC) Payloads; The Future of Antibody-Drug Conjugate (ADC) Payloads
£170.05
Anshan Ltd Inflammatory Breast Cancer: EXPLANATION, ADVICE,
Book Synopsis
£15.79
Anshan Ltd Breast Beating: A personal odyssey in the quest
Book Synopsis
£30.00
TFM Publishing Ltd Breast Lumps: A guide to diseases of the breast
Book SynopsisAny breast operation is a significant event. This book provides information to help to lessen the fear and gives practical advice for patients returning to a normal life.Table of ContentsContents include: an explanation of the benign causes of lumps and pain in the breast; an outline of the different types of cancer of the breast; a description of investigative and diagnostic procedures; a look at preparation for surgery; the different surgical procedures and what to expect after surgery; a discussion on radiotherapy and chemotherapy; an explanation of breast reconstruction.
£9.99
TFM Publishing Ltd Prostate Cancer: A comprehensive guide for
Book SynopsisThis book provides details of all the currently available information concerning the causes, prevention and treatment of prostate cancer, and aims to explain all aspects of the disease in terms that can be easily understood. It deals with the roles of complementary medicine and diet and other aspects for which there is growing evidence, but which many clinicians are reluctant to discuss with their patients.
£9.99
TFM Publishing Ltd A Guide to Cancer Genetics in Clinical Practice
Book SynopsisIntensive research over the last fifteen years has yielded a vast expansion in our understanding of the role of inheritance and genetics in a variety of cancers. Several inherited conditions have been identified which result in a high risk of various cancers; some of these were previously recognised, but the genetic basis underlying them has now been elucidated. This knowledge is now entering the sphere of routine clinical care. Once the preserve of researchers and highly specialised units, genetic testing for cancer predisposition is now accessible to most clinicians via regional genetics units; in the USA patients can access commercial genetic testing facilities. There is a growing evidence base to guide family screening and clinical management of affected individuals. Surgeons, gastroenterologists, gynaecologists, oncologists, endocrinologists and many others need an awareness of these disorders, an understanding of genetic testing and when it is indicated, and how to manage patients with inherited cancer predisposition and their families. Testing for these conditions has potential legal, ethical and financial implications different from those which most clinicians regularly encounter, and continuing scientific and clinical advance means that patients and their doctors will face regular changes in management. This book covers the basic concepts of cancer genetics. The common inherited cancer syndromes are each dealt with in greater depth, with the current management outlined. This book is aimed at all clinicians who may encounter these conditions in their practice. It aims to facilitate identification of high-risk individuals and families, to inform interaction with geneticists and other sub-specialists, to provide a basis for patient management and to stimulate interest in these fascinating conditions.
£27.00
JP Medical Ltd Bone and Soft Tissue Tumors: A Multidisciplinary
Book SynopsisThis is a comprehensive, lavishly illustrated review of orthopaedic oncology that is multi-disciplinary, integrative and highly practical. Introductory chapters cover overviews of the basics of bone and soft tissue tumors – the pathology, radiology and surgical and oncologic management. These are followed by chapters covering all tumor types organized according to the 2013 WHO classification of bone and soft tissue tumors. Each class of tumor is dealt with in detail, with case presentations illustrating how they would be diagnosed and managed in a clinical setting. The range of variation of each tumor type is indicated with appropriate radiological and pathological images. Detailed tables and flow charts provide quick access to vital diagnosis and staging information for each tumor type. This book provides an expert, case-based approach to orthopaedic oncology and patient care for trainees and practising orthopaedic surgeons, pathologists and radiologists. A practical and comprehensive review of orthopaedic oncology Covers all tumor types and their range of variation Organized according to the 2013 WHO classification of bone and soft tissue tumours Tables and flow charts provide diagnosis and staging information for each tumor type Trade Review"The book provides a library of useful solutions to real-life problems and provides valuable knowledge on data analysis and modeling, database design, implementation, and fine tuning."—Zentralblatt MATHTable of Contents1. Pathology of musculoskeletal tumors 2. Radiology overview of soft tissue and bone tumors 3. Surgery of musculoskeletal tumors: principles of diagnosis and treatment predictions for the future 4. Medical/Radiation Oncology of Musculoskeletal tumors 5. Adipocytic tumors 6. Fibroblastic/myofibroblastic tumors 7. "Fibrohistocytic" tumors of soft tissues 8. Muscle tumors of soft tissues 9. Pericytic/perivascular tumors 10. Vascular tumors of soft tissues 11. Chondro-osseous tumors of soft tissues 12. Myoepithelial tumors of soft tissue 13. Neural/perineural tumors and paraganglioma of soft tissue 14. Miscellaneous soft tissue tumors of uncertain differentiation 15. Metastatic tumors of soft tissue and bone 16. Cartilaginous tumors of bones and joints 17. Osteogenic tumors of bone 18. Fibrogenic tumors of bone 19. "Fibro-histiocytic" tumors of bone 20. Ewing sarcoma/PNET tumors of bone 21. Hematopoietic tumors of bone 22. Giant cell tumors of bone 23. Notochordal lesions of bone 24. Vascular tumors of bone 25. Uncommon primary bone tumors 26. Bone tumors of undefined nature 27. Benign mimics of bone and soft tissue tumors
£199.50
JP Medical Ltd Manual of Head and Neck Surgical Oncology
Book SynopsisTumors in the head and neck region often present the trainee or non-specialist surgeon with major challenges given the complexity of the regional anatomy. Manual of Head and Neck Surgical Oncology has been designed to provide trainee ENT Head & Neck surgeons and general surgeons with rapid access to the basic knowledge and principles required for management of the common tumors of the head and neck. Introductory chapters on the principles of chemotherapy, radiotherapy and imaging are followed by chapters devoted to specific procedures such as neck dissection, maxillectomy and skull base surgery. The book also includes information on nutritional and speech & language considerations. The chapters employ a consistent style to cover (1) the indications and preoperative considerations for each technique (2) a step by step guide to each procedure, using concise text, bullet-point lists and artworks which show the surgical approaches and (3) post-operative complications. Manual of Head and Neck Surgical Oncology is the ideal guide for all surgeons seeking a practical, accessible guide to the management of tumors of the head and neck. Concise, ‘how-to’ guide Focus on key principles and procedures Covers indications and contraindications, management principles and techniques, and complications and their avoidance Table of Contents Head and neck cancer: aetiology and epidemiology Imaging head and neck cancer Nutritional/SAL requirements Principles of chemotherapy Principles of radiotherapy Neck dissection Laryngectomy Tonsil/Soft palate surgery Tongue base surgery Medial maxillectomy via a lateral rhinotomy approach Maxillectomy Anterior cranial tumours including the pituitary fossa Application of functional endoscopic sinus surgery in head and neck oncology Glossectomy Management of the mandible in oral squamous cell carcinoma Parotid cancer Skull Base Surgery and the Infratemporal Fossa Skull base surgery Thyroid cancer Head and neck skin cancer Reconstruction of major defects
£80.75
JP Medical Ltd Handbook of Focal Therapy for Prostate and Renal
Book SynopsisProstate cancer is the commonest cancer in men. Current treatments include surgery to remove the whole prostate or radiotherapy of the whole prostate. These radical treatments can treat the cancer effectively but often cause unwanted side effects. Meanwhile widespread screening with prostate-specific antigen has led to an increased diagnosis of localised prostate cancer; at the same time, widespread use of abdominal imaging has led to increased detection of renal masses. In response to demand for improved outcomes with reduced side effects, focal therapy has emerged as an important procedure in managing both prostate and renal cancers. It targets individual areas of cancer, reducing unwanted side effects and the amount of damage to collateral tissue. This new method of treatment has major advantages: it involves less radiation, the removal of less tissue and less time spent in hospital. Handbook of Focal Therapy for Prostate and Renal Cancer provides a comprehensive, timely review of targeted ablation methods to treat prostate and renal cancers. It describes the most effective techniques in current practice, with discussion of the selection criteria, ablation technologies and their limitations, and advice on the management of common side effects. The book opens with a summary of the principles of prostate and renal cancer treatment and the mechanisms of focal therapy. Separate sections on prostate and kidney follow, covering the role of focal therapy, side effects and their treatment and follow-up after targeted ablation. Written in a practical, clinically-oriented style, Handbook of Focal Therapy for Prostate and Renal Cancer is the ideal reference for urologists, radiologists and radiation oncologists wishing to employ the latest focal therapy techniques in the care of their patients.Table of ContentsSECTION 1: RATIONALE FOR FOCAL TREATMENT OF PROSTATE AND RENAL CANCER Rationale for focal treatment Chapter 1 - The evolution from whole gland to focal treatment in contemporary oncology Chapter 2 - Mechanisms for cell death in ablative technologies Chapter 3 - How can focal treatment become recognized as a true alternative in prostate and renal cancer treatment? Rationale for focal treatment of prostate cancer Chapter 4 - Health-related quality of life implications of primary whole gland treatment of prostate cancer Chapter 5 - Salvage radical prostatectomy for recurrence of prostate cancer after radiation treatment Chapter 6 - Clinical utilization of novel biomarkers in the diagnostic and treatment paradigm and follow-up of prostate cancer Rationale for focal treatment of renal cancer Chapter 7 - From incidentaloma to renal cancer Chapter 8 - The need for better anatomical and histological characterization of small renal tumors before ablative therapy Chapter 9 - Every nephron counts: how to ensure optimal long-term renal function after treatment for renal cancer SECTION 2: PRACTICAL FOCAL TREATMENT OF PROSTATE CANCER Before treatment Chapter 10 - The role of TRUS-guided prostate biopsy in focal treatment of prostate cancer Chapter 11 - The role of MRI and image fusion-guided biopsies in focal treatment of prostate cancer Chapter 12 - Patient selection for focal treatment of prostate cancer Internally delivered energies Chapter 13 - Cryosurgical ablation of prostate cancer Chapter 14 - Focal laser ablation of prostate cancer Chapter 15 - Vascular targeted photodynamic treatment for prostate cancer Chapter 16 - Emerging technologies for focal ablation of prostate cancer: irreversible electroporation (IRE), laser ablation, and vapor technology Externally delivered energies Chapter 17 - High intensity focused ultrasound (HIFU) treatment of prostate cancer Chapter 18 - External radiation as a focal treatment of prostate cancer After treatment Chapter 19 - Side effects of focal treatment of prostate cancer Chapter 20 - Focal ablation as salvage treatment of prostate cancer Chapter 21 - Follow-up after focal treatment of prostate cancer SECTION 3: PRACTICAL FOCAL TREATMENT OF RENAL CANCER Before treatment Chapter 22 - Patient selection for focal treatment of renal cancer Surgical extirpation Chapter 23 - Surgical extirpation of renal cancer Laparoscopic guided ablation Chapter 24 - Laparoscopic-guided cryoablation and radio frequency ablation of renal cancer Percutaneous guided ablation Chapter 25 - Percutaneous image-guided radiofrequency ablation and cryoablation of renal cell carcinoma Chapter 26 - Emerging technologies for focal ablation of renal cancer After treatment Chapter 27 - Side effects of focal extirpation and ablation of renal cancer Chapter 28 - Salvage treatment of renal cancer after primary focal ablation failure Chapter 29 - Follow-up imaging after focal treatment of renal cancer
£80.75
Edward Everett Root Street-wise Patients' Guide to Surviving Cancer
Book SynopsisThe author is an internationally-famous cancer doctor. Former Chief, World Health Organisation. Cancer Programme. "This book is about what the NHS doesn''t tell you but what as a cancer patient you need to know. It is also a fascinating autobiography and medical history by one of the most famous cancer specialists in the country." - Professor Angus Dalgleish, St. George''s Hospital, London. "At last a reliable source of impartial advice which will empower patients to take control of their cancer treatment. The more patients understand the more they can take back control, get the best treatment for their cancer and move positively on. This book is just what we need. "All patients should read it, understand their cancer and what they can do to help themselves." - Professor Pat Price, Christie Hospital, Manchester.How to survive, and live with, cancer.?Short, sharp practical guide.?Shows patients how to can take control of their care. ?How to get the system to work for you. ?Gives 100 advisory websites, with expert notes. ?Absolutely up-to-date.
£40.00
Scientific Publishing Limited Understanding Breast Cancer Laminated Poster
Book Synopsis
£145.14